Anika Therapeutics Inc (ANIK) : Healthinvest Partners Ab reduced its stake in Anika Therapeutics Inc by 15.86% during the most recent quarter end. The investment management company now holds a total of 412,588 shares of Anika Therapeutics Inc which is valued at $21,693,877 after selling 77,743 shares in Anika Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Anika Therapeutics Inc makes up approximately 9.51% of Healthinvest Partners Ab’s portfolio.
Other Hedge Funds, Including , Smith Asset Management Group Lp reduced its stake in ANIK by selling 65,070 shares or 91.13% in the most recent quarter. The Hedge Fund company now holds 6,330 shares of ANIK which is valued at $332,831. Anika Therapeutics Inc makes up approx 0.01% of Smith Asset Management Group Lp’s portfolio.Eagle Ridge Investment Management reduced its stake in ANIK by selling 240 shares or 4.95% in the most recent quarter. The Hedge Fund company now holds 4,610 shares of ANIK which is valued at $241,472. Anika Therapeutics Inc makes up approx 0.05% of Eagle Ridge Investment Management’s portfolio.Acadian Asset Management reduced its stake in ANIK by selling 30,051 shares or 17.29% in the most recent quarter. The Hedge Fund company now holds 143,720 shares of ANIK which is valued at $7,483,500. Anika Therapeutics Inc makes up approx 0.04% of Acadian Asset Management’s portfolio.Eqis Capital Management boosted its stake in ANIK in the latest quarter, The investment management firm added 2,292 additional shares and now holds a total of 52,117 shares of Anika Therapeutics Inc which is valued at $2,726,240. Anika Therapeutics Inc makes up approx 0.18% of Eqis Capital Management’s portfolio.
Anika Therapeutics Inc opened for trading at $49.11 and hit $50.1 on the upside on Friday, eventually ending the session at $49.92, with a gain of 1.42% or 0.7 points. The heightened volatility saw the trading volume jump to 2,40,229 shares. Company has a market cap of $715 M.
On the company’s financial health, Anika Therapeutics Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.44. The company had revenue of $26.60 million for the quarter, compared to analysts expectations of $24.73 million. The company’s revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Anika Therapeutics Inc. Singular Research Upgraded Anika Therapeutics Inc on May 9, 2016 to ” Buy”, Price Target of the shares are set at $60.
Anika Therapeutics Inc. develops manufactures and commercializes therapeutic products for tissue protection healing and repair. The Company’s products are based on hyaluronic acid (HA) a naturally occurring biocompatible polymer found throughout the body. The Company’s wholly owned subsidiary Anika S.r.l. has about 20 products commercialized primarily in Europe. These products are also all made from HA based on two technologies: HYAFF which is a solid form of HA and ACP gel an autocross-linked polymer of HA. The Company’s technologies for modifying the HA molecule allow product properties to be tailored specifically to therapeutic use. The Company offers therapeutic products from these technologies in the areas of: Orthobiologics Dermal (Advanced wound care and Aesthetic dermatology) Surgical (Anti-adhesion and Ear nose and throat care (ENT)) Ophthalmic and Veterinary.